Wave’s PRISM platform is shifting the company from a setback-prone clinical story into a differentiated, multi-modality RNA medicines contender with near-term approval shots (DMD/AATD) and massive upside in muscle-sparing obesity.
Overview
Wave Life Sciences is a clinical-stage genetic medicines company focused on **RNA-targeted therapeutics** for both rare monogenic and prevalent genetically defined diseases, built on its proprietary **PRISM** discovery/development engine combining computational genetics, synthetic chemistry, and multiple RNA modalities. PRISM’s key differentiator is the ability to design **stereopure oligonucleotides**, improving target engagement, durability, and safety versus legacy stereorandom approaches that historically limited oligo delivery and tolerability. The current value is concentrated in four programs: **WVE‑007** (GalNAc-siRNA targeting INHBE for obesity with fat loss and muscle preservation, potentially once/twice-yearly dosing), **WVE‑006** (first-in-class GalNAc RNA editing for AATD via endogenous ADAR to correct SERPINA1 transcript), **WVE‑N531** (exon 53 skipping for DMD nearing pivotal/accelerated approval path), and **WVE‑003** (allele-selective Huntington’s). Strategically, Wave has pivoted away from the most challenging CNS-only bets toward systemic metabolic/hepatic opportunities, expanding TAM. Financially, the company is pre-commercial and currently relies on **collaboration revenue**—notably a major **GSK partnership** providing upfront non-dilutive funding and up to **$2.8B** in milestones plus royalties. 2025 collaboration revenue was **$42.7M** (down due to Takeda roll-off), but the company ended 2025 with **$602.1M cash**, funding operations into **3Q28**, positioning it to reach key 2026–2027 regulatory catalysts and potential late-decade commercialization.